Dechra Pharmaceuticals Delivers Another Solid Quarter
Edison | Apr 29, 2015 06:50AM ET
Trading update confirms progress on track
Dechra Pharmaceuticals (LONDON:DECP) has delivered another solid quarter with revenue growth up 6.0% (14.3% CER), resulting in nine-month growth of 6.6% (12.3% CER). Although boosted by phasing of pre-Easter ordering and competitor stock shortages in the US, the underlying growth confirms progress is on track and we leave our estimates unchanged. The core CAP products in Europe, coupled with the US product launches, more than offset the continuing weakness in FAP.
In Europe, reported sales fell 3.3% (+7.3% CER), resulting in a reported nine-month drop of 0.9% (+5.7% CER). Phasing of wholesale orders around the Easter break helped boost sales, with Companion Animal Products (CAP) up 13.5% CER and Equine rising by 30.2% (driven by the launch of Osphos). The Diets franchise was affected, as expected, by the transfer of production to a new contract manufacturer. Meanwhile, the well-flagged slowdown of antibiotic sales saw Food Producing Animal (FAP) revenues continuing to decline (-12.8% CER).
North American sales in the quarter increased 76.4% (66.8% CER), with nine-month growth being 69.0% (67.2% CER). This was driven by the launches of Phycox joint supplement, Osphos for navicular syndrome, and the re-launch of two Ophthalmology products after long-term supply issues were resolved. The dermatology product range also performed well as a competitor experienced stock problems. The Canadian subsidiary became fully operational in January 2015 and is included in these results. US revenues grew by 67.9% (57.7% CER) in the quarter and 65.7% (63.8% CER) for the nine months.
To Read the Entire Report Please Click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.